{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(2)"],"submitter":["Haeger A"],"pubmed_abstract":["PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [<sup>68</sup>Ga]Ga-DOTA-TATE. Al[<sup>18</sup>F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [<sup>68</sup>Ga]Ga-DOTA-TATE and Al[<sup>18</sup>F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [<sup>68</sup>Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[<sup>18</sup>F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adrenal glands (all <i>p</i> &lt; 0.001), pancreatic uncinated process, kidneys, and small intestine (all <i>p</i> &lt; 0.05). Nevertheless, despite the lower background uptake of Al[<sup>18</sup>F]F-NOTA-Octreotide, comparative analysis of tumour-to-liver (TLR) and tumour-to-spleen (TSR) showed no statistically significant difference for lesions in the liver, bone, lymph nodes, and other tissues. Only three discordant lesions in highly-metastases livers were detected by [<sup>68</sup>Ga]Ga-DOTA-TATE but not by Al[<sup>18</sup>F]F-NOTA-Octreotide and only one discordant lesion was detected by Al[<sup>18</sup>F]F-NOTA-Octreotide but not by [<sup>68</sup>Ga]Ga-DOTA-TATE. Non-inferiority analysis showed that Al[<sup>18</sup>F]F-NOTA-Octreotide is comparable to [<sup>68</sup>Ga]Ga-DOTA-TATE. Hence, our results demonstrate that Al[<sup>18</sup>F]F-NOTA-Octreotide provided excellent image quality, visualized NET lesions with high sensitivity and represents a highly promising, clinical alternative to [<sup>68</sup>Ga]Ga-DOTA-TATE."],"journal":["Cancers"],"pagination":["439"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856643"],"repository":["biostudies-literature"],"pubmed_title":["Al[<sup>18</sup>F]F-NOTA-Octreotide Is Comparable to [<sup>68</sup>Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population."],"pmcid":["PMC9856643"],"pubmed_authors":["Kramer V","Hurtado de Mendoza A","Eppard E","Emmanuel N","Soza-Ried C","Haeger A","Fernandez R","Wettlin J","Amaral H"],"additional_accession":[]},"is_claimable":false,"name":"Al[<sup>18</sup>F]F-NOTA-Octreotide Is Comparable to [<sup>68</sup>Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population.","description":"PET imaging of neuroendocrine tumours (NET) is well established for staging and therapy follow-up. The short half-life, increasing costs, and regulatory issues significantly limit the availability of approved imaging agents, such as [<sup>68</sup>Ga]Ga-DOTA-TATE. Al[<sup>18</sup>F]F-NOTA-Octreotide provides a similar biodistribution and tumour uptake, can be produced on a large scale and may improve access to precision imaging. Here we prospectively compared the clinical utility of [<sup>68</sup>Ga]Ga-DOTA-TATE and Al[<sup>18</sup>F]F-NOTA-Octreotide in the Latin-American population. Our results showed that in patients with stage IV NETs [<sup>68</sup>Ga]Ga-DOTA-TATE presents higher physiological uptake than Al[<sup>18</sup>F]F-NOTA-Octreotide in the liver, hypophysis, salivary glands, adrenal glands (all <i>p</i> &lt; 0.001), pancreatic uncinated process, kidneys, and small intestine (all <i>p</i> &lt; 0.05). Nevertheless, despite the lower background uptake of Al[<sup>18</sup>F]F-NOTA-Octreotide, comparative analysis of tumour-to-liver (TLR) and tumour-to-spleen (TSR) showed no statistically significant difference for lesions in the liver, bone, lymph nodes, and other tissues. Only three discordant lesions in highly-metastases livers were detected by [<sup>68</sup>Ga]Ga-DOTA-TATE but not by Al[<sup>18</sup>F]F-NOTA-Octreotide and only one discordant lesion was detected by Al[<sup>18</sup>F]F-NOTA-Octreotide but not by [<sup>68</sup>Ga]Ga-DOTA-TATE. Non-inferiority analysis showed that Al[<sup>18</sup>F]F-NOTA-Octreotide is comparable to [<sup>68</sup>Ga]Ga-DOTA-TATE. Hence, our results demonstrate that Al[<sup>18</sup>F]F-NOTA-Octreotide provided excellent image quality, visualized NET lesions with high sensitivity and represents a highly promising, clinical alternative to [<sup>68</sup>Ga]Ga-DOTA-TATE.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-22T01:09:33.245Z","creation":"2025-04-05T19:50:37.11Z"},"accession":"S-EPMC9856643","cross_references":{"pubmed":["36672388"],"doi":["10.3390/cancers15020439"]}}